Stay updated on Sotatercept in PAH: New Intermediate-High Risk Clinical Trial
Sign up to get notified when there's something new on the Sotatercept in PAH: New Intermediate-High Risk Clinical Trial page.

Latest updates to the Sotatercept in PAH: New Intermediate-High Risk Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check27 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed study objectives and participant criteria for a clinical trial on Pulmonary Arterial Hypertension, while adding identifiers and a revision note.SummaryDifference23%
- Check41 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 18, 2025. However, the removal of the date March 25, 2025, does not significantly impact the core content.SummaryDifference0.2%
- Check48 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to v2.14.3, replacing the previous date of February 18, 2025, and revision v2.14.2.SummaryDifference0.1%
- Check84 days agoChange DetectedThe webpage has been updated to reflect the closure of a study as of Amendment 11, allowing eligible participants to receive sotatercept through an extension study or commercial access. Additionally, the number of study locations has increased from 149 to 152, and specific locations in Taiwan have been added.SummaryDifference17%
- Check99 days agoChange DetectedThe web page has been updated to reflect a new version (v2.14.2) of the NLM-NCBI services and products, along with a notice about potential performance issues due to heavy traffic.SummaryDifference0.6%
Stay in the know with updates to Sotatercept in PAH: New Intermediate-High Risk Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sotatercept in PAH: New Intermediate-High Risk Clinical Trial page.